+

WO2003065977A3 - Cellules presentatrices d'antigene modifiees - Google Patents

Cellules presentatrices d'antigene modifiees Download PDF

Info

Publication number
WO2003065977A3
WO2003065977A3 PCT/US2002/037123 US0237123W WO03065977A3 WO 2003065977 A3 WO2003065977 A3 WO 2003065977A3 US 0237123 W US0237123 W US 0237123W WO 03065977 A3 WO03065977 A3 WO 03065977A3
Authority
WO
WIPO (PCT)
Prior art keywords
presenting cells
antigen
modified antigen
cells
relates
Prior art date
Application number
PCT/US2002/037123
Other languages
English (en)
Other versions
WO2003065977A2 (fr
WO2003065977A9 (fr
Inventor
Naoto Hirano
Marcus Butler
Lee M Nadler
Original Assignee
Dana Farber Cancer Inst Inc
Naoto Hirano
Marcus Butler
Lee M Nadler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc, Naoto Hirano, Marcus Butler, Lee M Nadler filed Critical Dana Farber Cancer Inst Inc
Priority to AU2002365938A priority Critical patent/AU2002365938A1/en
Priority to CA002467893A priority patent/CA2467893A1/fr
Priority to EP02806764A priority patent/EP1458241A4/fr
Publication of WO2003065977A2 publication Critical patent/WO2003065977A2/fr
Publication of WO2003065977A9 publication Critical patent/WO2003065977A9/fr
Publication of WO2003065977A3 publication Critical patent/WO2003065977A3/fr
Priority to US10/850,294 priority patent/US7955845B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention a trait à des cellules présentatrices d'antigène présentant une spécificité contre un antigène sélectionné et des procédés permettant la fabrication de telles cellules. L'invention a trait également à un procédé de sélection de cellules présentatrices d'antigène efficaces utilisant des constructions de fusion de gènes rapporteurs. Les cellules présentatrices d'antigène à efficacité élevée de l'invention fournissent un stratégie thérapeutique de modulation de réponses immunitaires pour une variété de maladies.
PCT/US2002/037123 2001-11-20 2002-11-20 Cellules presentatrices d'antigene modifiees WO2003065977A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002365938A AU2002365938A1 (en) 2001-11-20 2002-11-20 Modified antigen-presenting cells
CA002467893A CA2467893A1 (fr) 2001-11-20 2002-11-20 Cellules presentatrices d'antigene modifiees
EP02806764A EP1458241A4 (fr) 2001-11-20 2002-11-20 Cellules presentatrices d'antigene modifiees
US10/850,294 US7955845B2 (en) 2001-11-20 2004-05-20 Modified antigen-presenting cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33192801P 2001-11-20 2001-11-20
US60/331,928 2001-11-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/850,294 Continuation-In-Part US7955845B2 (en) 2001-11-20 2004-05-20 Modified antigen-presenting cells

Publications (3)

Publication Number Publication Date
WO2003065977A2 WO2003065977A2 (fr) 2003-08-14
WO2003065977A9 WO2003065977A9 (fr) 2003-10-16
WO2003065977A3 true WO2003065977A3 (fr) 2003-12-11

Family

ID=27734220

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/037123 WO2003065977A2 (fr) 2001-11-20 2002-11-20 Cellules presentatrices d'antigene modifiees

Country Status (4)

Country Link
EP (1) EP1458241A4 (fr)
AU (1) AU2002365938A1 (fr)
CA (1) CA2467893A1 (fr)
WO (1) WO2003065977A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7955845B2 (en) * 2001-11-20 2011-06-07 Dana Farber Cancer Institute, Inc. Modified antigen-presenting cells
WO2003057171A2 (fr) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation et developpement de lymphocytes t par mise en oeuvre d'une plate-forme de signalisation multivalente etablie
US7638326B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
JP5021309B2 (ja) 2003-10-16 2012-09-05 ステファン ジョン ラルフ 免疫調節性組成物およびその使用方法
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
LT3535290T (lt) * 2016-11-07 2024-02-12 Genovie Ab Genų inžinerijos būdu sudarytas dviejų dalių ląstelinis prietaisas t-ląstelių receptorių sąveikai su giminingu antigenu atrasti ir charakterizuoti
WO2018083316A1 (fr) 2016-11-07 2018-05-11 Genovie Ab Système à composants multiples génétiquement modifiés pour l'identification et la caractérisation de récepteurs de lymphocytes t et d'antigènes de lymphocytes t
CN110023497B (zh) 2016-11-07 2021-07-13 杰诺维有限公司 用于t细胞受体合成和向tcr呈递细胞进行稳定的基因组整合的两部分装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001080833A1 (fr) * 2000-04-20 2001-11-01 Salvatore Albani Procedes d'isolation, de quantification, de caracterisation et de modulation de cellules t specifiques des antigenes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024267A1 (fr) * 1993-04-20 1994-10-27 Robinson, William, S. Methode et materiel de traitement de patients infectes par des agents infectieux intracellulaires

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001080833A1 (fr) * 2000-04-20 2001-11-01 Salvatore Albani Procedes d'isolation, de quantification, de caracterisation et de modulation de cellules t specifiques des antigenes

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CAI Z. ET AL.: "Transfected drosophila cells as a probe for defining the minimal requirements for stimulating unprimed CD8+ T cells", PROC. NATL. ACAD. SCI. USA, vol. 93, December 1996 (1996-12-01), pages 14736 - 14741, XP000996637 *
FERRANDON D. ET AL.: "A drosomycin-GFP reporter transgene reveals a local immune response in drosophila the is not dependent on the Toll pathway", EMBO J., vol. 17, no. 5, 1998, pages 1217 - 1227, XP002971472 *
HIRANO N. ET AL.: "Protective and therapeutic immunity against leukemia induced by irradiated B7-1 (CD80)-transduced leukemic cells", HUMAN GENE THER., vol. 8, 20 July 1997 (1997-07-20), pages 1375 - 1384, XP002971475 *
HIRANO N. ET AL.: "Protective and therapeutic immunity against leukemia induced by irradiated B7-1 (CD80)-transduced leukemic cells", LEUKEMIA, vol. 11, pages 577 - 581, XP002971474 *
MARTI W.R. ET AL.: "Induction of antigen-presenting capacity in tumor cells upon infection with non-replicating recombinant vaccinia virus encoding murine MHC class II and costimulatory molecules", J. IMMUNOL. METH., vol. 200, 1997, pages 191 - 198, XP004016745 *
SCHOENBERGER S.P. ET AL.: "Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC", CANCER RES., vol. 58, 15 July 1998 (1998-07-15), pages 3094 - 3100, XP002971473 *

Also Published As

Publication number Publication date
WO2003065977A2 (fr) 2003-08-14
AU2002365938A8 (en) 2003-09-02
EP1458241A4 (fr) 2005-11-09
CA2467893A1 (fr) 2003-08-14
EP1458241A2 (fr) 2004-09-22
WO2003065977A9 (fr) 2003-10-16
AU2002365938A1 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
WO2005113589A3 (fr) Cellules de presentation de l'antigene modifiees
EP1149115A4 (fr) TECHNIQUES D'ELICITATION D'ANTICORPS NEUTRALISANTS CIBLANT gp41 DU VIH-1
WO2002033116A3 (fr) Ligands d'acides nucleiques de l'antigene membranaire prostatique specifique
IL212419A0 (en) Methods of administering anti-tnf antibodies
TW200515916A (en) Chimeric antigens for breaking host tolerance to foreign antigens
WO2003039470A3 (fr) Immunogene polyvalent
WO2004075850A3 (fr) Immunogene polyvalent
WO2003065977A3 (fr) Cellules presentatrices d'antigene modifiees
AU2001291019A1 (en) Method of modulating neovascularization
WO2003097810A3 (fr) Nitrilases, acides nucleiques les codant et leurs procedes de production et d'utilisation
AU2003300324A1 (en) Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
WO2003018600A3 (fr) Modulation antisens de l'expression de la proteine microsomale de transfert des triglycerides
AU2003235506A1 (en) Targeted enzymes and methods of making and using targeted enzymes.
AU2001280811A1 (en) Hybrid soybeans and methods of production
AU1777301A (en) Production of ungulates, preferably bovines that produce human immunoglobulins
WO1997011669A3 (fr) Antigenes limites du melanome, appartenant a la classe ii du mhc, et leur utilisation dans des methodes therapeutiques
AU2001249567A1 (en) Shaped springs and methods of fabricating and using shaped springs
AU2003276844A1 (en) Formulations of modified antibodies and methods of making the same
AU2002329534A1 (en) Modulation of antibody formation in mammals, applicability in gene therapy and animal model generation
WO2005016952A3 (fr) Immunogene polyvalent
AU1855001A (en) A new member of the pak protein family, nucleic acids and methods related to thesame
AU2003264319A1 (en) New tumor antigen vaccine and producing method and vaccine composition
WO2005059101A3 (fr) Nouveau canal sodique
WO1999016466A3 (fr) Compositions de vaccin et procedes servant a augmenter l'efficacite d'un vaccin
AU2002345658A1 (en) Methods for targeted expression of therapeutic nucleic acid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/11-11/11, DRAWINGS, REPLACED BY NEW PAGES 1/10-10/10; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 2467893

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10850294

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002806764

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002806764

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002806764

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载